Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 28 drug safety PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


drug safety PhD Projects, Programmes & Scholarships

We have 28 drug safety PhD Projects, Programmes & Scholarships

Evaluation of cardiac safety features of over-the-counter medications

It is now well-established that a number of prescription medications are linked to a low, but significant risk of alterations to the QT interval of the electrocardiogram and with an associated dangerous arrhythmia called torsades de pointes. Read more

Precision Medicine DTP - AI-driven drug discovery for diseases of unmet need with high-throughput phenomics data

Abstract. Drug discovery is extremely expensive and most candidate compounds fail at various stages of clinical trials. Artificial Intelligence (AI) has recently emerged as a promising tool to accelerate the search for new active compounds. Read more

Molecular characterisation of a novel transporter for the atypical antipsychotic clozapine

Schizophrenia is a severe psychiatric illness affecting about 24 million people worldwide. Schizophrenia can have a devastating effect on a patient’s life and is associated with increased mortality, with life expectancy reduced on average by 15 years compared to that of the general population. Read more
Last chance to apply

Subgroup effects in antihypertensive and type 2 diabetes drug classes: a comparative effectiveness and safety study integrating real-world and genetic data

Commercial partner: Janssen. Pharmaceutical Companies of Johnson & Johnson. Estimating subgroup treatment effects from clinical trials is notably difficult due to the limited sample size and under-representation of patients with multimorbidity. Read more

Identifying new drug targets within Mycobacterium tuberculosis

Tuberculosis (TB) is the leading cause of death worldwide and reflects a serious global health challenge. This bacterial pathogen kills more people than malaria and HIV combined, and is increasingly developing resistance to many of the current front-line drugs. Read more

Combining laser and ultrasound based molecular delivery strategies for enhanced drug delivery

Overview. This project addresses the critical area of delivering therapeutics to the skin. If successful, the approach will have direct and positive consequences for the treatment of a range of skin diseases, but may also be viewed as a more generic means of drug delivery for treating a much wider range of disease. Read more

Innovative chemical modification of antimicrobial peptides; enhancing bioactivity and investigating mode of action

Project ID. SST_SHiMR_15. In 2014 the O’Neill report estimated that unless urgent action is taken, deaths caused by antimicrobial resistant (AMR) infections will raise to 10 million annually by 2050, surpassing cancer as the greatest single cause of death due to disease. Read more

Modification of antibiotics to improve efficacy / safety

With increasing concern over antibiotic resistance, antibacterial agents such as chloramphenicol and colistin, which have frequently been passed over in the past because of concerns over toxicity, are now becoming more important to tackle resistant bacterial strains. . Read more

Designs for sequences of early phase (modular) studies

Background to the project. An emerging setting is to conduct a trial of an experimental drug as monotherapy, then in combination(s) with previously studied agents, and then to proceed into expansion cohorts (called modular trials). Read more

Optimising deep brain stimulation for treatment of epilepsy: a networks based approach

This PhD provides the opportunity to work with clinicians and scientists from GOS Institute of Child Health and a UK based biotechnology SME, Amber therapeutics, to develop deep brain stimulation (DBS) techniques for the treatment of childhood epilepsy. Read more

The development of new antiviral agents targeting HIV-1

Even before the current global COVID-19 pandemic, the threat posed to human health by viruses was extensive and although significant progress in targeting some viruses (e.g., HIV-1 and hepatitis C) has been made, challenges remain. Read more

Filtering Results